CONCERT PHARMACEUTICALS, INC. 4
4 · CONCERT PHARMACEUTICALS, INC. · Filed Feb 21, 2014
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2014-02-20+106,194→ 1,058,920 total(indirect: See Footnote) - Purchase
Common Stock
2014-02-20$14.00/sh+150,000$2,100,000→ 1,208,920 total(indirect: See Footnote) - Conversion
Series A Convertible Preferred Stock
2014-02-20−2,200,000→ 0 total(indirect: See Footnote)→ Common Stock (389,380 underlying) - Conversion
Common Stock
2014-02-20+389,380→ 421,752 total(indirect: See Footnote) - Conversion
Series C Convertible Preferred Stock
2014-02-20−600,000→ 0 total(indirect: See Footnote)→ Common Stock (106,194 underlying) - Conversion
Common Stock
2014-02-20+530,974→ 952,726 total(indirect: See Footnote) - Conversion
Series B Convertible Preferred Stock
2014-02-20−3,000,000→ 0 total(indirect: See Footnote)→ Common Stock (530,974 underlying)
Footnotes (3)
- [F1]The Series A, Series B and Series C Convertible Preferred Stock converted into Common Stock on a 1-for-5.65 basis upon the closing of the issuer's initial public offering without payment of consideration.
- [F2]Held by Skyline Venture Partners Qualified Purchaser Fund IV L.P. Dr. John G. Freund and Dr. Yasunori Kaneko are Managing Members of Skyline Venture Management IV, LLC, which is the sole general partner of Skyline Venture Partners Qualified Purchaser Fund IV, L.P., and as such may be deemed to share voting and dispositive power with respect to all shares held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. Drs. Freund and Kaneko disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. Dr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports.
- [F3]Not applicable.